Article
Oncology
Matthew L. Fisher, Seamus Balinth, Yon Hwangbo, Caizhi Wu, Carlos Ballon, John E. Wilkinson, Gary L. Goldberg, Alea A. Mills
Summary: BRD4 plays a critical role in the regulation of cancer stem-like properties and is highly elevated in the aggressive subpopulation of cells in squamous cell carcinomas. Targeting BRD4 can effectively inhibit Delta Np63 alpha, reducing spheroid formation and inhibiting tumor growth.
Article
Oncology
Rebecca S. Hesterberg, Min Liu, Aya G. Elmarsafawi, John M. Koomen, Eric A. Welsh, Stephen G. Hesterberg, Sujeewa Ranatunga, Chunying Yang, Weimin Li, Harshani R. Lawrence, Paulo C. Rodriguez, Anders E. Berglund, John L. Cleveland
Summary: Chronic T-cell receptor (TCR) signaling in the tumor microenvironment leads to T-cell dysfunction, and poorly immunogenic tumors compromise T cells by impairing their metabolism. Increasing lymphoma burden significantly affects CD4(+) T-cell function and promotes regulatory T cell (Treg) and Th1-cell differentiation. Early reprogramming and impairment of CD4(+) T-cell metabolism, glucose uptake, and mitochondrial function precede changes in T-cell fate. In contrast, B-cell lymphoma metabolism remains robust during tumor progression. Furthermore, mitochondrial functions are impaired in CD4(+) and CD8(+) T cells in lymphoma-transplanted OT-II and OT-I transgenic mice respectively. These findings support a model where early, TCR-independent, metabolic interactions with developing lymphomas limit T cell-mediated immune surveillance.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Medical Laboratory Technology
Huixian Ma, Xiangrui Luo, Peng Zhou, Na He, Jun Zhou, Min Liu, Wei Xie
Summary: The study identified that the deubiquitinase USP21 promotes cell proliferation by stabilizing the EZH2 protein level in DLBCL, without affecting cell death. This mechanism further reveals the pathogenesis of DLBCL.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2021)
Article
Oncology
Boheng Li, Qidi Zhou, Qin Wan, Xuan Qiao, Shangying Chen, Jianbiao Zhou, Zhijun Wuxiao, Lei Luo, Siok-Bian Ng, Jieping Li, Wee-Joo Chng
Summary: This study identifies TRIP12 as an E3 ligase that triggers polyubiquitination of EZH2, leading to its stabilization and promoting ENKTL cell migration. The TRIP12-EZH2 axis can be regulated by cytoplasmic HSP60 and targeted by dexamethasone treatment.
CLINICAL EPIGENETICS
(2023)
Article
Oncology
Julie Devin, Tatiana Caneque, Yea-Lih Lin, Lucie Mondoulet, Jean-Luc Veyrune, Matthieu Abouladze, Elvira Garcia De Paco, Ouissem Karmous Gadacha, Guillaume Cartron, Philippe Pasero, Caroline Bret, Raphael Rodriguez, Jerome Moreaux
Summary: Diffuse large B-cell lymphoma (DLBCL) is a common hematological malignancy, and alterations in iron metabolism may be targeted for therapy. Iron score (IS), a gene expression-based risk score, can identify high-risk DLBCL patients who may benefit from targeting iron homeostasis. Ironomycin, a potential treatment for DLBCL, inhibits cell proliferation and induces cell death.
Article
Hematology
Takashi Ishio, Sarvesh Kumar, Joji Shimono, Anusara Daenthanasanmak, Sigrid Dubois, Yuquan Lin, Bonita Bryant, Michael N. Petrus, Emmanuel Bachy, Da Wei Huang, Yandan Yang, Patrick L. Green, Hiroo Hasegawa, Michiyuki Maeda, Hideki Goto, Tomoyuki Endo, Takashi Yokota, Kanako C. Hatanaka, Yutaka Hatanaka, Shinya Tanaka, Yoshihiro Matsuno, Yibin Yang, Satoshi Hashino, Takanori Teshima, Thomas A. Waldmann, Louis M. Staudt, Masao Nakagawa
Summary: The study identifies CDK6 as a novel therapeutic target for adult T-cell leukemia/lymphoma (ATLL) and suggests the potential of combining CDK6 inhibitor palbociclib with mTORC1 inhibitors for treating this difficult malignancy.
Article
Multidisciplinary Sciences
Dhananjaya Pal, Kendra R. Vann, Shweta Joshi, Namood E. Sahar, Guillermo A. Morales, Dalia El-Gamal, Tatiana G. Kutateladze, Donald L. Durden
Summary: The study developed a first-in-class inhibitor SRX3262 that simultaneously blocks three driver pathways of MCL and overcomes resistance. The inhibitor destabilizes c-MYC, induces apoptosis, providing a new approach to treat MCL.
Article
Biochemistry & Molecular Biology
Mariangeles Clauzure, Monica A. Taquez Delgado, Jude M. Phillip, Maria V. Revuelta, Leandro Cerchietti, Vanina A. Medina
Summary: The discovery of the human histamine H4 receptor (H4R) and its function in aggressive T-cell lymphoma has provided insights into the role of histamine in tumor development and progression. Histamine and specific H4R agonists reduced cell viability in a dose-dependent manner, while H4R antagonist reversed these effects. Additionally, combining histamine with certain FDA-approved compounds showed favorable antitumor effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Health Care Sciences & Services
Sara Petronilho, Jose Pedro Sequeira, Sofia Paulino, Paula Lopes, Susana Lisboa, Sergio Chacim, Joao Lobo, Manuel Teixeira, Carmen Jeronimo, Rui Henrique
Summary: The study found that EZH2 expression levels were not associated with prognosis in DLBCL and HGBCL patients, but EZH2/BCL2 co-expression was significantly correlated with worse outcomes. These findings suggest that the use of EZH2 antagonists may benefit non-GC DLBCL patients.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Pathology
Aresu Sadeghi Shoreh Deli, Sonja Scharf, Yvonne Steiner, Julia Bein, Martin-Leo Hansmann, Sylvia Hartmann
Summary: This study aimed to understand the differences between NLPHL and THRLBCL by measuring nuclear and cell size features in 2D and 3D sections. The findings revealed that THRLBCL tumor cells have larger nuclear volume and cell size compared to typical NLPHL cases in 3D measurements. T cells in THRLBCL also showed increased nuclear volume, suggesting their strong activation and frequent contact with tumor cells. Further molecular studies combining 3D tissue analyses and molecular data are needed to gain a better understanding of these cellular processes.
Review
Oncology
Allison C. Rosenthal, Javier L. Munoz, J. C. Villasboas
Summary: Advancements in cancer biology, genomics, epigenomics, and immunology have expanded cancer treatment options beyond chemotherapy or radiotherapy. This review focuses on the latest applications of epigenetic therapies for B cell, T cell, and Hodgkin lymphomas, covering key clinical trial results for monotherapies and combination therapies.
CLINICAL EPIGENETICS
(2023)
Article
Hematology
Niklas Gebauer, Hanno M. Witte, Hartmut Merz, Ilske Oschlies, Wolfram Klapper, Almuth Caliebe, Lars Tharun, Malte Spielmann, Nikolas von Bubnoff, Alfred C. Feller, Eva M. Murga Penas
Summary: A recent discovery of Burkitt-like lymphoma with 11q aberration (BLL-11q) suggests that 11q abnormalities can be found in both BLL in the context of an underlying HIV infection and in high-grade B-cell lymphomas with MYC, BCL2, and/or BCL6 rearrangements. This indicates that the clinicopathological spectrum of malignancies carrying this aberration may be broader than previously assumed.
Article
Biochemistry & Molecular Biology
Rajan Kumar Tiwari, Shiv Govind Rawat, Vishal Kumar Gupta, Pradip Kumar Jaiswara, Pratishtha Sonker, Santosh Kumar, Vibhav Gautam, Manoj K. Mishra, Ajay Kumar
Summary: Recent studies have found that stress-regulatory hormones, such as epinephrine, play a role in regulating the progression of certain cancers. However, little is known about the tumor-promoting action of epinephrine in T cell malignancy. This study investigates the role of epinephrine in T lymphoma cell proliferation and glucose metabolism. The results show that epinephrine enhances cell proliferation and inhibits apoptosis, possibly through regulating the expression of key proteins involved in these processes. Additionally, epinephrine stimulates glycolysis in T lymphoma cells and increases the production of reactive oxygen species, which may contribute to tumor growth. Overall, this study suggests that epinephrine may have a significant role in the progression of T cell lymphoma.
CHEMICO-BIOLOGICAL INTERACTIONS
(2023)
Article
Oncology
Hepei Yuan, Momoko Nishikori, Yasuyuki Otsuka, Hiroshi Arima, Toshio Kitawaki, Akifumi Takaori-Kondo
Summary: Tazemetostat can potentially activate anti-lymphoma response by upregulating CCL17 expression in B-cell lymphoma cells and promote T-cell recruitment, providing a rationale for its combination with immunotherapy.
Article
Oncology
Yanchun Ma, Vera Bauer, Tanja Riedel, Fatima Ahmetlic, Nadine Homberg, Thomas P. Hofer, Martin Rocken, Ralph Mocikat
Summary: The study reveals that IL-10 suppresses ongoing immune responses in lymphoma and may be a potential target for immunotherapy.
